ALTEOGEN Inc.
Research ALTEOGEN Inc. (196170) on Bullrun: market cap KRW 22.26T, dividend yield 0.1%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker196170
- ExchangeKQ
- CountrySouth Korea
- SectorHealthcare
- IndustryBiotechnology
- CurrencyKRW
- Market capKRW 22.26T
- Dividend yield0.1%
- Financial periodQ1 2026
- RevenueKRW 71.60B
- Net incomeKRW 71.70B
- Free cash flowKRW 6.78B
- Gross margin85.9%
Valuation Snapshot
latest market cap is KRW 22.26T; dividend yield is 0.1%.
Peer valuation comparison
Latest dividend yield is 0.12% versus a Healthcare sector median of 2.11% (94.3% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | KRW 215.86B | KRW 141.67B | KRW 90.71B | 76.7% | n/a | KRW 66.38B | KRW 7.06B | KRW 445.19B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-28 | KRW 22.26T | n/a | 0.1% | 285.38 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 285.38 KRW, yield 0.1%.
About ALTEOGEN Inc.
ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. The company develops ALT-P1, a long-acting human growth hormone that is in the Phase IIa clinical trial; and ALT-Q2, a long-acting active form of coagulation factor VII for the treatment of hemophilia based on its NexP technology. It is also involved in the development of ALT-P7, a targeted breast/gastric cancer drug that is in the Phase I clinical trial;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is ALTEOGEN Inc.'s market cap?
ALTEOGEN Inc.'s market capitalization is KRW 22.26T.
Does ALTEOGEN Inc. pay a dividend?
ALTEOGEN Inc. has a dividend yield of 0.1%.
What does ALTEOGEN Inc. do?
ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. The company develops ALT-P1, a long-acting human growth hormone that is in the Phase IIa clinical trial; and ALT-Q2, a long-acting active form of coagulation factor VII for the treatment of hemophilia based on its NexP technology.